| Project/Area Number |
20591858
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Kagawa University |
|---|
Principal Investigator |
WU Xiu-Xian Kagawa University, 医学部, 助教 (10346645)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TSUNEMORI Hiroyuki 香川大学, 医学部附属病院, 助教 (20380173)
SUGIMOTO Mikio 香川大学, 医学部附属病院, 准教授 (10243768)
INUI MASASHI 香川大学, 医学部附属病院, 講師 (40314918)
KAKEHI Yoshiyuki 香川大学, 医学部, 教授 (20214273)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2010: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2009: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2008: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
|---|
| Keywords | TRAIL-R2 / laxatumumab / アドリアマイシン / 腎癌細胞 / カスパーゼ / アポトーシス / lexatumumab / Laxatumumab |
|---|
| Research Abstract |
Development of anti-TRAIL receptor antibody in combination with chemotherapeutic therapy against advanced genitourinary cancers was performed. We found : (1) anti-TRAIL death receptor 2 antibody lexatumumab in combination with clinically achievable concentrations of adriamycin, cisplastin, epirubicin, or pirarubicin had a synergistic cytotoxic effect ; (2) the synergistic cytotoxicity was significantly inhibited by caspase inhibitors demonstrating caspase cascade, especially caspase-8 plays an important role in the synergy ; (3)PCR array analysis identified 26 genes related with apoptosis.
|
